Abciximab
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
dalteparin
Low-molecular-weight heparin · Anticoagulant
Low-molecular-weight heparinAnticoagulant
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
B
FDA category + note
Top interactionssee all 12 →
- AbciximabSevereDatabaseDDInter
- AcalabrutinibSevereDatabaseDDInter
- AlteplaseSevereDatabaseDDInter
- AnagrelideSevereDatabaseDDInter
Mechanism
Not yet extracted
Indications
initial treatment of venous thromboembolismacute coronary syndromeProphylaxis of deep vein thrombosisProphylaxis of pulmonary embolism (in high-risk patients undergoing surgery; stroke or other immobilized patients)Treatment of established deep vein thrombosisUnstable anginaMyocardial infarctionMaintain patency of cannulae and shunts in dialysis patientsTreatment of venous thromboembolism associated with cancer (compared to apixaban)Prophylaxis for hospitalized cancer patientsProphylaxis for cancer patients receiving a thalidomide analogueVTEprophylaxis for VTE
Dosing
- Adult
- Prophylaxis: 2500 IU OD; Treatment of deep vein thrombosis: 100 U/Kg 12 hourly or 200 U/Kg 24 hourly
- Pediatric
- May require monitoring
- Renal adjustment
- May require monitoring with an anti–factor Xa assay due to accumulation and bleeding risk. Contraindicated in patients with creatinine clearance below 30 mL/min.
Pharmacokinetics
Half-life
4-6 hours
Bioavailability
90% after subcutaneous injection
Excretion
Cleared almost exclusively by the kidneys
Contraindications
- Creatinine clearance below 30 mL/min
Side effects
Common
Bleeding (somewhat less incidence than unfractionated heparin)Little effect on plateletsReversible abnormalities of hepatic function tests
Serious
- Thrombocytopenia (<1% incidence)
- Osteoporosis (lower risk than unfractionated heparin)
- Hyperkalemia
Pregnancy & lactation
Pregnancy
B
Drug interactions
Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alteplase
Severe
Database
Clinical effect not specified
Source: DDInter
Anagrelide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Anisindione
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Anistreplase
Severe
Database
Clinical effect not specified
Source: DDInter
Antithrombin Alfa
Severe
Database
Clinical effect not specified
Source: DDInter
Antithrombin Iii Human
Severe
Database
Clinical effect not specified
Source: DDInter
Apixaban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Ardeparin
Severe
Database
Clinical effect not specified
Source: DDInter
Argatroban
Severe
Database
Clinical effect not specified
Source: DDInter
Aspirin
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Related guidelines
Other Low-molecular-weight heparin drugs
Ask House about dalteparin
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: KD Tripathi 7e, Goodman & Gilman 14e, Harrison 22e·Updated: 2026-05-10